Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Patients with advanced-stage NETs showed significantly lower L1-L4 BMD (bone mineral density), L1-L4 T-score, L1-L4 Z-score, 25-hydroxyvitamin D [25(OH)D] levels and BMI than those with earlier-stage disease.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This cross-sectional study included 41 patients with grade (G) 1, 2, or 3 gastroenteropancreatic (GEP) and lung NETs.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Bone health in neuroendocrine tumors and prognostic implications beyond skeletal metastases

Cross-sectional study · Frontiers in Endocrinology · 2026

Original publication title

Bone health in neuroendocrine tumors and prognostic implications beyond skeletal metastases

Andrea Casabella; Iderina Hasballa; Anna Arecco; Mara Boschetti; Leonardo Della Sala; Davide Demontis; Alberto Sulli; Lara Vera; Alessandro Veresani; Diego Ferone; Sabrina Paolino; Manuela Albertelli

Copyright © 2026 Casabella, Hasballa, Arecco, Boschetti, Della Sala, Demontis, Sulli, Vera, Veresani, Ferone, Paolino and Albertelli.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

NET patients showed a substantial burden of musculoskeletal impairment, with trabecular microarchitecture deterioration detectable despite BMD versus healthy controls. Advanced disease stage, higher grade and systemic treatment were associated with poorer bone health. Increased vitamin D levels and BMI were independently associated with longer PFS, supporting a potential relationship between nutritional-metabolic status and oncological outcomes. Low muscle mass was also frequent, although not significantly associated with tumor aggressiveness. These exploratory findings highlight the need for structured musculoskeletal assessment in NET patients and require validation in larger prospective studies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To assess the musculoskeletal status, its prognostic relevance and association with tumor aggressiveness in NET patients.

Source: Aim

Abstract: What methods does the paper describe?

This cross-sectional study included 41 patients with grade (G) 1, 2, or 3 gastroenteropancreatic (GEP) and lung NETs. Among them, 38 were selected for comparison with 47 healthy controls matched for age, sex and body mass index (BMI). The musculoskeletal health was assessed by dual-energy X-ray absorptiometry (DXA) scan.

Source: Materials and methods

Abstract: Results

Within the NET group (median age=72 years old, 46% women), degraded TBS (trabecular bone score) was found in 71% of patients, with osteopenia affecting up to 59% at the femoral neck. The prevalence of hypovitaminosis D was 68%, whereas of low RSMI (relative skeletal muscle index) suggestive of sarcopenia 37%. Patients with advanced-stage NETs showed significantly lower L1-L4 BMD (bone mineral density), L1-L4 T-score, L1-L4 Z-score, 25-hydroxyvitamin D [25(OH)D] levels and BMI than those with earlier-stage disease. G2 NETs were associated with worse L1-L4 BMD, L1-L4 T-score, total hip T-score and diaphysis BMD than G1 NETs.

In multivariate analysis, higher 25(OH)D levels and BMI were independently associated with longer progression-free survival (PFS), whereas higher Ki-67 was associated with shorter PFS. Correlation analyses showed inverse associations between Ki-67 and total hip T-score (rho = -0.314, p=0.048) and diaphysis BMD (rho = -0.354, p=0.025); age at NET diagnosis correlated with poorer bone parameters, whereas higher BMI was associated with better bone indices and RSMI. Compared with healthy controls, NET patients had significantly lower TBS, regardless of BMD, T-score or Z-score.

Source: Results

Abstract: Conclusion

NET patients showed a substantial burden of musculoskeletal impairment, with trabecular microarchitecture deterioration detectable despite BMD versus healthy controls. Advanced disease stage, higher grade and systemic treatment were associated with poorer bone health. Increased vitamin D levels and BMI were independently associated with longer PFS, supporting a potential relationship between nutritional-metabolic status and oncological outcomes. Low muscle mass was also frequent, although not significantly associated with tumor aggressiveness. These exploratory findings highlight the need for structured musculoskeletal assessment in NET patients and require validation in larger prospective studies.

Source: Conclusion
Authors’ abstract

Background

The potential impact of NET (neuroendocrine tumor)-related disease burden on musculoskeletal health remains inconclusive.

Aim

To assess the musculoskeletal status, its prognostic relevance and association with tumor aggressiveness in NET patients.

Materials and methods

This cross-sectional study included 41 patients with grade (G) 1, 2, or 3 gastroenteropancreatic (GEP) and lung NETs. Among them, 38 were selected for comparison with 47 healthy controls matched for age, sex and body mass index (BMI). The musculoskeletal health was assessed by dual-energy X-ray absorptiometry (DXA) scan.

Results

Within the NET group (median age=72 years old, 46% women), degraded TBS (trabecular bone score) was found in 71% of patients, with osteopenia affecting up to 59% at the femoral neck. The prevalence of hypovitaminosis D was 68%, whereas of low RSMI (relative skeletal muscle index) suggestive of sarcopenia 37%. Patients with advanced-stage NETs showed significantly lower L1-L4 BMD (bone mineral density), L1-L4 T-score, L1-L4 Z-score, 25-hydroxyvitamin D [25(OH)D] levels and BMI than those with earlier-stage disease. G2 NETs were associated with worse L1-L4 BMD, L1-L4 T-score, total hip T-score and diaphysis BMD than G1 NETs.

In multivariate analysis, higher 25(OH)D levels and BMI were independently associated with longer progression-free survival (PFS), whereas higher Ki-67 was associated with shorter PFS. Correlation analyses showed inverse associations between Ki-67 and total hip T-score (rho = -0.314, p=0.048) and diaphysis BMD (rho = -0.354, p=0.025); age at NET diagnosis correlated with poorer bone parameters, whereas higher BMI was associated with better bone indices and RSMI. Compared with healthy controls, NET patients had significantly lower TBS, regardless of BMD, T-score or Z-score.

Conclusion

NET patients showed a substantial burden of musculoskeletal impairment, with trabecular microarchitecture deterioration detectable despite BMD versus healthy controls. Advanced disease stage, higher grade and systemic treatment were associated with poorer bone health. Increased vitamin D levels and BMI were independently associated with longer PFS, supporting a potential relationship between nutritional-metabolic status and oncological outcomes. Low muscle mass was also frequent, although not significantly associated with tumor aggressiveness. These exploratory findings highlight the need for structured musculoskeletal assessment in NET patients and require validation in larger prospective studies.

Publication and source details

Original title: Bone health in neuroendocrine tumors and prognostic implications beyond skeletal metastases

Andrea Casabella; Iderina Hasballa; Anna Arecco; Mara Boschetti; Leonardo Della Sala; Davide Demontis; Alberto Sulli; Lara Vera; Alessandro Veresani; Diego Ferone; Sabrina Paolino; Manuela Albertelli

Frontiers in Endocrinology · 2026

* Correspondence: Iderina Hasballa, ihasballa@yahoo.com

†These authors have contributed equally to this work and share first authorship

Copyright © 2026 Casabella, Hasballa, Arecco, Boschetti, Della Sala, Demontis, Sulli, Vera, Veresani, Ferone, Paolino and Albertelli.2026Casabella, Hasballa, Arecco, Boschetti, Della Sala, Demontis, Sulli, Vera, Veresani, Ferone, Paolino and Albertellihttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:11:41.196162+00:00

DOI: 10.3389/fendo.2026.1882735 · PMC13368541